Skip to main content

Table 1 Baseline characteristics of participants. eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; OGTT, oral glucose tolerance test, PCR, protein creatinine ratio; TG, triglycerides. NS is not significant when P-value is > 0.05.

From: Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation

 

Group 1 (Standard care)

Group 2 (Intervention)

P-value

Number of patients

9

10

 

Females

2 (22%)

6 (60%)

0.04

Age (years)

48.5 (SD 11.6)

43.4 (SD 9.3)

NS

Fasting glucose (mmol/L)

5.3 (SD 0.7)

5.4 (SD 0.4)

NS

2 h glucose at OGTT (mmol/L)

9.3 (SD 0.84)

9.8 (SD 0.7)

NS

Body mass index

28.9 (SD 5.6)

26.9 (SD 4.8)

NS

Hba1c (mmol/mol)

35.8 (SD 5.5)

33.8 (SD 3.7)

NS

Creatinine (micromol/L)

136.3 (SD 36.6)

111.4 (SD 37.9)

NS

eGFR in MDRD (ml/min)

55.1 (SD 16.5)

61.4 (SD 20)

NS

GI quality of life

3.1 (SD 3.4)

1.4 (SD 2.5)

NS

Serum cholesterol (mmol/L)

6.2 (SD 1.1)

6.2 (SD 1.2)

NS

Serum TG (mmol/L)

2 (SD 0.9)

2.6 (SD 1)

NS

Systolic BP (mm Hg)

142.3 (SD 16.3)

125.3 (SD 11.4)

NS

Diastolic BP (mm Hg)

85.3 (SD 8.8)

78.9 (SD 7.7)

NS

Duration between transplant and enrolment

31.8 (SD 6.8)

42.3 (SD 19.8)

0.001

Urine PCR (mg/mmol)

36 (SD 22.2)

53.8 (SD 35.4)

NS

Steroids dose at randomisation (mg)

17.5 (SD 2.6)

13.9 (SD 3.3)

0.024

Number of patients on tacrolimus

3 (33%)

6 (60%)

NS

  1. “Bold entries have clinical significance”